Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 3/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | PEPD | P12955 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL29222416 | 1.00 | LMNA (0.53) | LMNACA1CA2CA9SLC34A1 | |
| Phosphoric Acid SCHEMBL7772392 | 1.00 | LMNA (0.53) | LMNACA1CA2CA9SLC34A1 | |
| Phosphoric Acid SCHEMBL25433301 | 0.96 | LMNA (0.50) | LMNACA1CA2CA9SLC34A1 | |
| Phosphoric Acid SCHEMBL4107573 | 0.96 | LMNA (0.50) | LMNACA1CA2CA9SLC34A1 | |
| Phosphoric Acid SCHEMBL5503120 | 0.96 | LMNA (0.50) | LMNACA1CA2CA9SLC34A1 | |
| Phosphoric Acid SCHEMBL10360253 | 0.92 | LMNA (0.47) | LMNACA1CA2CA9SLC34A1 | |
| Phosphoric Acid SCHEMBL3446211 | 0.91 | LMNA (0.47) | LMNACA1CA2CA9SLC34A1 | |
| Phosphoric Acid SCHEMBL4339227 | 0.91 | LMNA (0.47) | LMNACA1CA2CA9SLC34A1 | |
| Phosphoric Acid SCHEMBL28444166 | 0.91 | LMNA (0.47) | LMNACA1CA2CA9SLC34A1 | |
| Phosphoric Acid SCHEMBL38659102 | 0.91 | LMNA (0.47) | LMNACA1CA2CA9SLC34A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 286 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110664732-A | Antitumor complexes and related methods of production | 贝塔格鲁技术股份公司 | 2020-01-10 | — | — | CN | claimed |
| CN-108329385-A | A kind of preparation method of regenerated silk fibroin solution | 苏州先蚕丝绸有限公司 | 2018-07-27 | — | — | CN | claimed |
| CN-105778124-B | Biodegradable medical aquogel and preparation method and application | 山东赛克赛斯生物科技有限公司 | 2017-12-05 | — | — | CN | claimed |
| US-20140248209-A1 | ANTI-TUMORAL COMPOUND AND RELATIVE PRODUCTION PROCESS | SEVENTEEN SRL (IT) | 2014-09-04 | — | — | US | claimed |
| EP-2768482-A1 | ANTI-TUMORAL COMPOUND AND RELATIVE PRODUCTION PROCESS | Seventeen Srl (IT) | 2014-08-27 | — | — | EP | claimed |
| CN-103889402-A | Antitumor complexes and related methods of production | SEVENTEEN SRL | 2014-06-25 | — | — | CN | claimed |
| WO-2013057747-A1 | ANTI-TUMORAL COMPOUND AND RELATIVE PRODUCTION PROCESS | SEVENTEEN SRL (IT) | 2013-04-25 | — | — | WO | claimed |
| CN-101534753-B | bone cement mixing systems and related methods | WYETH (US) | 2011-12-28 | — | — | CN | claimed |
| JP-2010502379-A | — | — | 2010-01-28 | — | — | JP | claimed |
| CN-101534753-A | Bone cement mixing systems and related methods | WYETH CORP (US) | 2009-09-16 | — | — | CN | claimed |
| EP-2059196-A2 | BONE CEMENT MIXING SYSTEMS AND RELATED METHODS | Wyeth (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2008030742-A2 | BONE CEMENT MIXING SYSTEMS AND RELATED METHODS | WYETH (US) | 2008-03-13 | — | — | WO | claimed |
| US-20080065088-A1 | Bone Cement Mixing Systems and Related Methods | WYETH (US) | 2008-03-13 | — | — | US | claimed |
| US-20230414861-A1 | COMPOSITIONS, DEVICES AND KITS FOR SELECTIVE INTERNAL RADIATION THERAPY | BetaGlue Technologies S.p.A (IT) | 2023-12-28 | — | — | US | disclosed |
| US-20230270685-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | MODERNATX, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| US-11724023-B2 | Compositions, devices and kits for selective internal radiation therapy | BetaGlue Technologies S.p.A (IT) | 2023-08-15 | — | — | US | disclosed |
| WO-1993010212-A1 | THIN MEMBRANE SENSOR WITH BIOCHEMICAL SWITCH | CASE GEORGE D (US) | 1993-05-27 | — | — | WO | disclosed |
| US-4808422-A | Center-filled food products | FRITO-LAY, INC. (US) | 1989-02-28 | — | — | US | disclosed |
| US-4613509-A | Process for producing center-filled food products | FRITO-LAY, INC. (US) | 1986-09-23 | — | — | US | disclosed |
| US-4189396-A | TITANIUM OR ZIRCONIUM PEROXO COMPOUNDS | LEVER BROTHERS COMPANY (US) | 1980-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270685-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | POLM, EMG1, MCM6 | LMNA 594/4885CA1 4424/4885CA2 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.